Skip to main content

Table 3 Univariate and multivariate analyses of disease-free survival in patients with hormone receptor-positive/HER2-negative primary breast cancer

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

   Univariate Multivariate
   Total (n=142) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Ki67-p53 Low Ki67 LI and Negative p53 88 1    1   
  High Ki67 LI and/or Positive p53 54 9.3 3.5-24.5 < 0.0001 11.6 4.2-32.3 < 0.0001
FOXA1 Low 20 1      
  High 119 1.4 0.51-3.6 0.54    
GATA3 Negative 30 1      
  Positive 112 1.5 0.65-3.5 0.34    
Basal phenotype marker Negative 9 1      
(CK5/6, CK14, EGFR) Positive 133 1.0 0.24-4.3 0.98    
P-cadherin Low 90 1      
  High 52 1.3 0.59-2.8 0.52    
Tumor size <5.0 cm 17 1    1   
  5.0 cm 122 4.9 2.1-11.4 0.0003 5.7 2.3-14.1 0.0002
Lymph-node metastasis (−) 80 1      
  (+) 59 3.8 1.6-8.8 0.0020    
Nuclear grade 1, 2 111 1      
  3 31 4.2 1.9-9.0 0.0002    
Chemotherapy No 93 1    1   
  Yes 49 2.6 1.2-5.7 0.014 3.5 1.5-7.9 0.0028
  1. Abbreviation: 95%CI 95% confidence interval, LI labeling index.